Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | APP | P05067 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | INSR | P06213 | 1/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27557266 | 1.00 | MEN1 (0.66) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL30803727 | 0.92 | MEN1 (0.56) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL6482082 | 0.92 | MEN1 (0.56) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL30446667 | 0.92 | MEN1 (0.56) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL25673149 | 0.92 | MEN1 (0.56) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL319385 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL319386 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTRAB9AAPP | |
| SCHEMBL29559249 | 0.87 | MEN1 (0.77) | MEN1KMT2AMAPTRAB9AAPP | |
| Dimethylamine SCHEMBL11573253 | 0.86 | MAPT (0.67) | MEN1KMT2AMAPTRAB9AAPP | |
| Alanine SCHEMBL1245505 | 0.86 | ALOX5 (0.53) | MEN1KMT2AMAPTRAB9AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-04-19 | — | — | US | disclosed |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2008-06-26 | — | — | US | disclosed |
| US-7351401-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, MAPT, PSEN2 | MEN1 2567/4885KMT2A 3526/4885MAPT 2/4885 |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MEN1 2842/4885KMT2A 3801/4885MAPT 3/4885 |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MEN1 2819/4885KMT2A 3728/4885MAPT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.